FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03841110 |
Recruitment Status :
Completed
First Posted : February 15, 2019
Last Update Posted : May 1, 2023
|
Sponsor:
Fate Therapeutics
Information provided by (Responsible Party):
Fate Therapeutics
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | November 15, 2022 |
Actual Study Completion Date : | November 15, 2022 |